Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Multivariable Fine–Gray sub-distribution hazards analysis of mortality in idiopathic pulmonary fibrosis patients who were and were not treated with antifibrotics with time-dependent covariates: study cohort

From: Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias

 

No. of patients

HR

95%CI

p-value

Unexposed

15,632

Ref

Ref

Ref

Nintedanib

6766

   

 Unadjusted

 

0.93

0.89–0.98

0.0027

 Adjusted a

 

0.85

0.81–0.89

< 0.0001

Pirfenidone

7055

   

 Unadjusted

 

1.06

1.02–1.10

0.0046

 Adjusted a

 

0.89

0.86–0.93

< 0.0001

  1. The start of antifibrotic treatment was used as a time-dependent covariate
  2. Lung transplantation was treated as a competing event
  3. aAdjusted for age, sex, cerebrovascular disease, dementia, acquired immunodeficiency syndrome/human immunodeficiency virus, myocardial infarction, renal disease, congestive heart failure, peripheral vascular disease, chronic pulmonary disease, peptic ulcer, liver disease, diabetes mellitus, hemiplegia or paraplegia, venous thromboembolic disease, pulmonary hypertension, long-term oxygen use, and corticosteroid use at baseline
  4. CI, confidence interval; HR, hazard ratio
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us